CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 252 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02185014
NCT02185014Phase 3Completed
CompareCT.gov

A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease

AbbVie·interventional·Posted Jul 9, 2014·Updated Nov 14, 2018

In Brief

A Phase 3 clinical trial evaluating Adalimumab for Crohn's Disease. Completed, enrolled 252 participants.

Detailed Summary

The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 9, 2014
Enrollment StartAug 12, 2014
Primary CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.0 years ago

Interventions

Adalimumabdrug

Adalimumab pre-filled syringe, administered by subcutaneous injection